A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study

A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study

Abstract Background We report a case of neuromyelitis optica spectrum disorders (NMOSD), who developed after the pembrolizumab treatment, an immune checkpoint inhibitor, against lung adenocarcinoma. The present case is discussed with the lung adenocarcinoma specimen which was stained by aquaporin-4...

Full description

Bibliographic Details
Main Authors: Shigeki Hirano, Akira Kojima, Yoko Nakayama, Takahiro Takeda, Takashi Kishimoto, Toshiyuki Takahashi, Satoshi Kuwabara, Masahiro Mori
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Neurology
Subjects:
Neuromyelitis optica spectrum disorders
Immune checkpoint inhibitor
Pembrolizumab
Case report
Aquaporin-4
Online Access:https://doi.org/10.1186/s12883-022-02987-6

Internet

https://doi.org/10.1186/s12883-022-02987-6

Similar Items